That is likely because of the ability of ibrutinib to focus on irreversibly both BTK and EGFR family and block re-activation of PI3K/AKT or MAPK due to growth factors such as for example NRG1 in vivo. BTK prevents activation from the AKT signaling pathway by NRG or EGF that is proven to promote development factor-driven […]